Wanbury Ltd has reported a net sales of Rs 92.52 crore for the quarter ended March 31, 2010, compared to Rs 84.01 crore in the corresponding quarter of last fiscal. The standalone net profit was Rs 14.49 crore, compared to a net loss of Rs 34.95 crore in the corresponding quarter of last fiscal. For the year ended March 2010, the company on a standalone basis reported a net sales of Rs 351.10 crore and a net profit of Rs 29.92 crore.
On a consolidated basis, Wanbury has reported a net sales of Rs 472.58 crore for the year ended March 2010. The net profit was at Rs 8.41 crore. EPS for Q4F Y10 worked out to Rs. 9.86.
Wanbury Ltd is the fastest growing pharmaceutical company among the top 100 companies. The company has strong presence in domestic formulations, Active Pharmaceutical Ingredient (API) and Contract Research and Manufacturing Services (CRAMS). Wanbury also has presence in Europe in formulations. Wanbury offers the best in class services related to research, development and manufacturing of chemicals, intermediates, active pharmaceutical ingredients and finished formsto the life science industry.
The company has a fast growing presence in CRAMS catering to large MNCs globally for manufacturing their products. Wanbury has its sales office in Zurich, Switzerland and caters to the US and European markets through its US FDA plants.
Wanbury is the largest manufacturer of some of its products in APIs, which include Metformin, Tramadol and Salsalate. The company exports to over 70 countries, 65 per cent of which is to the regulated markets. Wanbury has two US FDA approved multi-product API facilities for regulated markets. The company has filed over 27 DMFs (Drug Master Files). Wanbury has pan India presence in ethical formulations with a portfolio of over 70 brands. As per ORG-IMS, it ranks 43rd and is the fastest growing company in the domestic market.
Cpink, launched by the company was awarded ‘Best Launch’ of the year by ORG-IMS in India. Four of the company products viz. Cpink, Rabiplus, Folinine and Adtrol are in the ‘Top 3’ brands in respective segments. Wanbury has presence in branded ethical finished dosage forms in Spain through Cantabria Pharma SL, its subsidiary. Cantabria Pharma SL, head quartered at Madrid, which employs over 100 people caters to key therapeutic areas like psychiatry, CNS, CVS, respiratory and pain management.